


Common Reasons to Order PGx Testing


A

When the FDA requires/recommends pharmacogenomics (PGx) testing for that medication or medications on the package insert¹

Black Box Warning 


T

When the patient has had a severe adverse drug reaction(s) or complications due to medications^{2,3,4}




G

There is a family history of a serious adverse drug reaction or known pharmacogenomic variant³



C

Identifying patients who require a higher or lower - than - standard dose of a medication^{2,7}



A

When patients have experienced multiple treatment failures^{6,7,8}



T

The recommended drug dosage has not relieved symptoms or the patient has sensitivity to a medication⁷




Common Reasons to Order PGx Testing


T When a patient is experiencing unexpected or exaggerated response(s) to a medication(s)³



A To improve a patient's medication compliance/adherence^{5,8}



G For patients who are on multiple medications^{9,10,11}



C PGx testing can be taken preemptively so the results can be readily available when needed¹¹



References:

1. U.S. Food & Drug Administration-Table of Pharmacogenomic Biomarkers in Drug Labeling- <https://www.fda.gov/drugs/science-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling>
2. Plumpton, C.o., et al. "Cost Effectiveness of Pharmacogenetic Screening Prior to Initiation of Carbamazepine Treatment for Epilepsy." *Value in Health*, vol. 16, no. 7, 2013, doi:10.1016/j.jval.2013.08.1831.
3. Dorfman, Ruslan, et al. "Application of Personalized Medicine to Chronic Disease: A Feasibility Assessment." *Clinical and Translational Medicine*, vol. 2, no. 1, 2013, p. 16, doi:10.1186/2001-1326-2-16.
4. Alagoz, O, et al. "Cost-Effectiveness of One-Time Genetic Testing to Minimize Lifetime Adverse Drug Reactions." *The Pharmacogenomics Journal*, vol. 16, no. 2, 2015, pp. 129–136, doi:10.1038/tpj.2015.39.
5. Belle, Donna. "Genetic Factors in Drug Metabolism." *American Academy of Family Physicians*, 2008 Jun 1;77(11): 1553–60.
6. Bradley, Paul, et al. "Improved Efficacy with Targeted Pharmacogenetic-Guided Treatment of Patients with Depression and Anxiety: A Randomized Clinical Trial Demonstrating Clinical Utility." *Journal of Psychiatric Research*, vol. 96, 2018, pp. 100–107.
7. Winner, Joel G., et al. "Combinatorial Pharmacogenomic Guidance for Psychiatric Medications Reduces Overall Pharmacy Costs in a 1 Year Prospective Evaluation." *Current Medical Research and Opinion*, vol. 31, no. 9, 2015, pp. 1633–1643, doi:10.1185/03007995.2015.1063483.
8. Isidoro-García-a, MarÁ-a, et al. "Primun Non Nocere, Polypharmacy and Pharmacogenetics." *Pharmacogenomics*, vol. 16, no. 17, 2015, pp. 1903–1905., doi:10.2217/pgs.15.137.
9. D. Brixner et al., The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. *Journal of medical economics* 19, 213-228 (2016).
10. J. S. Saldivar et al., Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility. *Pharmacogenomics and personalized medicine* 9, 1-6 (2016).
11. Van Driest, Sara L. et al. "Clinically Actionable Genotypes among 10,000 Patients with Preemptive Pharmacogenomic Testing." *Clinical pharmacology and therapeutics* 95.4 (2014): 423–431